Abstracts tagged "Lupus and neuropsychiatric disorders"

Abstract Number: 2095 • 2018 ACR/ARHP Annual Meeting
Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
Michelle Huang¹, Ariel Stock² and Chaim Putterman³, ¹Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Despite the many lupus patients affected by neuropsychiatric signs and symptoms, the pathogenesis of neuropsychiatric disease in SLE remains unclear. MRL-lpr/lpr mice, a classic…
Abstract Number: 711 • 2017 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Depressive Disorders in Chinese Patients with Systemic Lupus Erythematosus (SLE)
Chi Chiu Mok¹, Yan Tung Lilian Lo², Chi Wai Cheng² and Kam Shan Poon², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Psychiatry, Castle Peak Hospital, Hong Kong, Hong Kong
Background/Purpose: Depression is common in SLE but most previous studies utilized self-rated scales for evaluation. Formal diagnosis of depression was not established by psychiatric interviews.…
Abstract Number: 97 • 2017 Pediatric Rheumatology Symposium
Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis
Renee F Modica¹, Kathleen M Vazzana², Natalie Jane Shiff³, Akaluck Thatayatikom³ and Melissa E Elder¹, ¹Department of Pediatrics, University of Florida, Gainesville, FL, ²Pediatrics, University of Florida at Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, ³Pediatrics, University of Florida, Gainesville, FL
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) with psychosis is challenging to treat with refractory cases often requiring prolonged hospitalization due to significant functional impairment and…
Abstract Number: 2056 • 2016 ACR/ARHP Annual Meeting
Choroid Plexus Infiltrates in Lupus Model (MRL/lpr) Mice Represent Tertiary Lymphoid Structures, Shedding Light on the Immunological Mechanisms of Neuropsychiatric Lupus
Ariel Stock¹, Sivan Gelb², Ayal Ben-Zvi² and Chaim Putterman³, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Hebrew University, Jerusalem, Israel, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: MRL/lpr mice develop an overt neuropsychiatric phenotype including depression and cognitive dysfunction, similar to diffuse neuropsychiatric manifestations of human lupus. Additionally, MRL/lpr mice display…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].